Relationship of MTHFR gene polymorphisms with renal and cardiac disease

Figure 1 Odds to renal failure-hemodialysis. Comparison of the wild MTHFR genotype in dialysis patients (36/160; 22.5%) vs the No-HD group (58/470; 12.3%): P < 0.003; OR = 2.062 (95%CI: 1.3-3.273), i.e., the wild MTHFR genotype bears a double risk of renal failure in comparison with all MTHFR polymorphisms and a four-fold risk vs the Homozygous C677T MTHFR polymorphism. The individual odds of renal failure, according to the specific MTHFR polymorphism status are as follows (hemodialysis patients 160 vs No-HD group 470) are not significant, with the exception of the Homozygous C677T MTHFR polymorphism which exhibits a protective behavior. Heterozygous C677T (28/160 vs 90/470); P = NS. OR = 0.896 (95%CI: 0.561-1.43); Heterozygous A1298C (20/160 vs 56/470); P = NS. OR = 1.056 (95%CI: 0.612-1.822); Compound Heterozygous C677T and A1298C (40/160 vs 118/470); P = NS. OR = 0.994 (95%CI: 0.657-1.505); Homozygous A1298C (20/160 vs 62/470); P = NS. OR = 0.94 (95%CI: 0.548-1.612); Homozygous C677T (16/160 vs 88/470); P = 0.015. OR = 0.482 (95%CI: 0.274-0.85). MTHFR: Methylenetetrahydrofolate reductase; OR: Odds ratio; NS: Not significant.